MCL1 and hepatocellular carcinoma: In multi-HCC cell lines, sorafenib downregulates phosphorylated STAT3 (p-STAT3) and decreases the expression of myeloid leukemia-1 (MCL-1), thereby breaking down the Beclin1-MCL-1 complex and inducing autophagy.